. 2005 Jan;43(1):484–487. doi: 10.1128/JCM.43.1.484-487.2005

TABLE 2.

Treatment-associated changes selected in the PR genes of HIV-2-infected patients receiving a PI-containing regimen

First-line PI regimen	At baseline				At time of protease gene genotyping
	Patient	Subtype	Viral load (cells/ml)	CD4 cells/mm³	Viral load (cells/ml)	CD4 cells/mm³	PI regimen	Mo from start of therapy	Amino acid changes in the PR gene during therapy
	Patient	Subtype	Viral load (cells/ml)	CD4 cells/mm³	Viral load (cells/ml)	CD4 cells/mm³	PI regimen	Mo from start of therapy	Amino acid changes known to be involved in HIV-1 resistance	Amino acid changes of unknown impact in HIV-1 resistance^a
IDV	1	A	<250	231	ND^b	445	IDV	8	—^c	T80Y/T
	2	A	19800	64	836	44	IDV	26	I36I/V	R70K
	3	A	250	252	3,855	173	IDV	6	—	—
	4	A	16980	8	14,545	152	IDV	21	V10I, I82F, L90L/M	K7N, F85L, I89V
					188,500	93	SQV/R	26	V10I, I82F, I84V, L90M	S43I, R70K, I84L, F85L, I89V
	5	A	360	360	84,000	246	IDV	7	I82F	—
					4,220	209	IDV	9	V10I, I82F	I89I/V
					355	238	SQV/R	46	V10I, T77T/I, I82F, I84L, L90M	A34S, K65K/R, F85F/L, I89V, A92A/V
	6	B	<250	31	<250	83	IDV	14	—	L23M, S40N, T43I, K45R, I64V, I82M
					<250	92	SQV/R	19	V10V/I, I54I/L, I84V	L23M, S40N, T43I, K45R, 146I/T, E63E/A, I64V, I95V, I82M
	7	C	10,530	315	1,470	450	IDV	9	—	N41Y
					3,935	293	IDV	24	I82F	I15I/V, A34E, N41Y
					<250	501	IDV	36	I82F	A34E, N41Y
					2,580	492	IDV	48	I82F	A34E, N41Y/H, R72K, M95M/I
SQV	8	A	<250	262	<250	251	SQV	2	—	—
	9	A	15,000	42	3,240	111	SQV/R	12	I46I/V	I36V, G48G/R
	10	A	490	249	531	350	SQV	14	I54L, L90M	—
					1,583	123	NFV	55	V10I, I84V, L90M	E63Q, V71I
	11	B	<250	86	<250	146	SQV/R	31	—	—
RTV	12	A	16,450	24	20,780	38	RTV	9	I82F	G55R/G
					58,080	21	SQV/R	23	—	S40D, K60R
	13	A	4,780	42	5,177	106	RTV	6	I54I/M, V71V/A, L90L/M	L38L/F, K45K/R, I64I/V
					12,840	77	NFV	16	I54M, L90M	I64V, V71V/I
NFV	14	A	1,485,000	48	39,840	80	NFV	12	I54M	V71V/I, T74N
					9,316	95	NFV	14	I54M, L90M	V71V/I, T74N
	15	A	97,980	257	1,058	154	NFV	7	L90M	V71I, A92A/V
	16	B	<250	359	<250	331	NFV	11	V33J	I15V, T56A, V71I, R87K
					<250	237	NFV	25	F53F/V33J	I15V, I32L, T56A, V62A, V71I, G78G/E
	17	B	<260	296	<250	398	NFV	20	—	V22I, K45R, T56A, I64V

*, amino acid changes associated with polymorphism of the PR gene in HIV-2 are underlined.

ND, not determined.

—, None.